KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Operating Expenses: 2009-2025

Historic Other Operating Expenses for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to $5.1 million.

  • Biomarin Pharmaceutical's Other Operating Expenses fell 6.77% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $153.8 million, marking a year-over-year increase of 1815.71%. This contributed to the annual value of $10.0 million for FY2024, which is 126.17% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Other Operating Expenses stood at $5.1 million for Q3 2025, which was up 5.38% from $4.8 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Other Operating Expenses peaked at $162.9 million during Q4 2022, and registered a low of -$19.9 million during Q4 2023.
  • Over the past 3 years, Biomarin Pharmaceutical's median Other Operating Expenses value was -$817,000 (recorded in 2023), while the average stood at $11.5 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Other Operating Expenses skyrocketed by 22,006.69% in 2022, and later plummeted by 523.32% in 2023.
  • Biomarin Pharmaceutical's Other Operating Expenses (Quarterly) stood at $1.4 million in 2021, then skyrocketed by 11,477.97% to $162.9 million in 2022, then slumped by 112.21% to -$19.9 million in 2023, then skyrocketed by 832.69% to $145.8 million in 2024, then declined by 6.77% to $5.1 million in 2025.
  • Its Other Operating Expenses stands at $5.1 million for Q3 2025, versus $4.8 million for Q2 2025 and -$2.0 million for Q1 2025.